Immuneering Corporation IMRX announced that it has entered into a clinical supply agreement with pharma giant Eli Lilly LLY ...

Immuneering sold: (i) an aggregate of 6,329,113 unregistered shares of the company’s Class A common stock at a purchase price of $3.95 per share (or, for certain investors in lieu of Class A common ...

Immuneering (IMRX) partners with Eli Lilly to test atebimetinib + olomorasib in a phase 2 trial targeting KRAS G12c-mutant ...

Immuneering to evaluate atebimetinib in combination with olomorasib in planned Phase 2 trial in patients with advanced non-small cell lung ...

Immuneering Corporation (IMRX) on Monday announced a clinical supply agreement with Eli Lilly and Company (LLY) for the ...

Encouraging early data for IMRX's atebimetinib in RAS-driven cancers sparks interest, but financial and clinical risks ...

Investing.com -- Immuneering Corp (NASDAQ:IMRX) stock surged 21.7% Monday after the clinical-stage oncology company announced ...

Eli Lilly (LLY) announced positive results from the Phase 3 ATTAIN-2 trial for orforglipron, a potential treatment for ...

Shares of Immuneering rose after the company entered into a clinical supply agreement for Eli Lilly's olomorasib drug to support testing of Immuneering's proposed lung-cancer treatment. The stock was ...

Immuneering said investors agreed to buy roughly 6.3 million shares of its Class A common stock for $3.95 a piece. In lieu of Class A common stock, certain investors will buy pre-funded warrants to ...

CAMBRIDGE, Mass., June 17, 2025 (GLOBE NEWSWIRE) -- Immuneering Corporation (Nasdaq: IMRX), a clinical-stage oncology company outpacing cancer to help patients outlive their disease, today ...

Immuneering’s lead product candidate, IMM-1-104, is an oral, once-daily Deep Cyclic Inhibitor currently in a Phase 1/2a trial in patients with advanced solid tumors including those harboring RAS ...